uniQure (NASDAQ:QURE) Shares Gap Down - What's Next?

Key Points

• uniQure N.V. shares gapped down to $51.00 from a previous close of $52.65, with last trading at $50.39 and a significant trading volume of over 3.8 million shares.
• Multiple brokerages have significantly raised their price targets for uniQure, with Goldman Sachs setting it at $56.00 and Guggenheim at $95.00, reflecting a consensus rating of "Buy" and a price target of $67.17.
• uniQure reported an EPS of ($0.69) for the last quarter, beating expectations, and has seen notable institutional investment with 78.83% of the stock owned by institutional investors.

uniQure N.V. (NASDAQ:QURE - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $52.65, but opened at $51.00. uniQure shares last traded at $50.39, with a volume of 3,812,931 shares changing hands.

Analyst Ratings Changes

A number of brokerages have weighed in on QURE. The Goldman Sachs Group upped their price target on shares of uniQure from $13.00 to $56.00 and gave the company a "neutral" rating in a report on Thursday. Wells Fargo & Company upped their price target on shares of uniQure from $30.00 to $65.00 and gave the company an "overweight" rating in a report on Thursday. Guggenheim boosted their price objective on uniQure from $28.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday. Mizuho boosted their price objective on uniQure from $30.00 to $60.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $67.17.

uniQure Stock Up 0.7%

The company has a market cap of $2.91 billion, a price-to-earnings ratio of -13.56 and a beta of 0.14. The business has a fifty day moving average price of $16.65 and a two-hundred day moving average price of $14.61. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The business had revenue of $5.26 million during the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC boosted its position in shares of uniQure by 12.5% in the first quarter. Sanders Morris Harris LLC now owns 114,887 shares of the biotechnology company's stock valued at $1,139,000 after acquiring an additional 12,783 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock valued at $3,550,000 after acquiring an additional 261,323 shares during the period. Mraz Amerine & Associates Inc. bought a new stake in shares of uniQure in the first quarter valued at approximately $106,000. Diamond Hill Capital Management Inc. boosted its position in shares of uniQure by 22.8% in the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company's stock valued at $876,000 after acquiring an additional 15,333 shares during the period. Finally, XTX Topco Ltd boosted its position in shares of uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 20,720 shares during the period. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.